41 results about "Melanoma inhibitory activity" patented technology

The invention discloses lactobacillus plantarum with the inhibitory activity to alpha-glucosidase. The lactobacillus plantarum is classified and named as Lactobacillus plantarum, is preserved on August 29, 2017 in China General Microbiological Culture Collection Center and has a preservation number of CGMCC NO.14573. By screening, the lactobacillus plantarum has in-vitro inhibitory activity to alpha-glucosidase; the survival rate of the lactobacillus plantarum reaches up to 71.04% under an acid condition that the pH value is 2.0 and is 77.14% in 2.0% cholate deionized water, the tolerances of the lactobacillus plantarum to artificially simulated saliva and intestinal fluid are higher than 90%, the tolerance of the lactobacillus plantarum to gastric fluid reaches 52.49%, and after artificially simulated fluid is sequentially digested, the survival rate reaches 88.27%; the lactobacillus plantarum has good effects on the prevention and treatment of diabetes mellitus type 2; the lactobacillus plantarum is added with a protection agent so as to prepare freeze-drying battier powder with a high viable count, and the viable count reaches up to 87% of the viable count before freeze-drying; and besides, the lactobacillus plantarum further has a good fermentation effect.

The present invention is directed to new bifunctional compounds and methods for treating HIV infections. The bifunctional small molecules, generally referred to as ARM-H′ function through orthogonal pathways, by inhibiting the gp120-CD4 interaction, and by recruiting anti-DNP antibodies to gp120-expressing cells, thereby preventing cell infection and spread of HIV. It has been shown that ARM-H's bind to gp120 and gp-120 expressing cells competitively with CD4, thereby decreasing viral infectivity as shown by an MT-2 cell assay, the binding leading to formation of a ternary complex by recruiting anti-DNP antibodies to bind thereto, the antibodies present in the ternary complex promoting the complement-dependent destruction of the gp120-expressing cells. Compounds and methods are described herein.

The invention provides mastic tetracyclic triterpenoid components with 11 beta-hydroxysteroid dehydrogenase 1 inhibitory activity, a composition of the mastic tetracyclic triterpenoid components and application, and novel application of mastic tetracyclic triterpenoid components with structures of the general formulas I-IV as 11 beta-HDS inhibitors. As a class of 11 beta-HSD inhibitors in novel structure types, the mastic tetracyclic triterpenoid components have certain selective inhibition effects on 11 beta-HSD1 and are expected to be developed into medicine for regulating lipid metabolism and treating diabetes, obesity, cardiovascular diseases and the like.

Drug candidates for inhibition of HIV-I replication can target Src family kinases (SFK), such as Hck, that interact with Nef protein of the virus. Compounds characterized by such inhibitory activity were identified via an assay for kinase activity of an SFK in a Nef:SFK complex. Illustrative of inhibitors identified using the kinase assay are various 2,3-diaminoquinaxolines and furo[2,3-d]pyrimidines. The inventive inhibitors were found to arrest HIV-I viral replication in vitro.